Discovery and characterization of single-domain antibodies for polymeric Ig receptor-mediated mucosal delivery of biologics.


Journal

mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829

Informations de publication

Date de publication:
Historique:
pubmed: 8 1 2020
medline: 13 2 2021
entrez: 8 1 2020
Statut: ppublish

Résumé

Mucosal immunity is dominated by secretory IgA and IgM, although these are less favorable compared to IgG molecules for therapeutic development. Polymeric IgA and IgM are actively transported across the epithelial barrier via engagement of the polymeric Ig receptor (pIgR), but IgG molecules lack a lumen-targeted active transport mechanism, resulting in poor biodistribution of IgG therapeutics in mucosal tissues. In this work, we describe the discovery and characterization of single-domain antibodies (VHH) that engage pIgR and undergo transepithelial transport across the mucosal epithelium. The anti-pIgR VHH panel displayed a broad range of biophysical characteristics, epitope diversity, IgA competition profiles and transcytosis activity in cell and human primary lung tissue models. Making use of this diverse VHH panel, we studied the relationship between biophysical and functional properties of anti-pIgR binders targeting different domains and epitopes of pIgR. These VHH molecules will serve as excellent tools for studying pIgR-mediated transport of biologics and for delivering multispecific IgG antibodies into mucosal lumen, where they can target and neutralize mucosal antigens.

Identifiants

pubmed: 31906797
doi: 10.1080/19420862.2019.1708030
pmc: PMC6973331
doi:

Substances chimiques

Biological Products 0
Immunoglobulin G 0
Receptors, Polymeric Immunoglobulin 0
Single-Domain Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1708030

Références

J Clin Invest. 1993 Nov;92(5):2394-400
pubmed: 8227356
J Biol Chem. 2012 Jun 1;287(23):19399-408
pubmed: 22518843
Cell Mol Life Sci. 2019 Mar;76(6):1041-1055
pubmed: 30498997
Am J Respir Cell Mol Biol. 1999 Aug;21(2):246-52
pubmed: 10423408
Traffic. 2010 Sep;11(9):1205-20
pubmed: 20525015
Structure. 2004 Nov;12(11):1925-35
pubmed: 15530357
Mucosal Immunol. 2011 Nov;4(6):590-7
pubmed: 21937984
Immunol Rev. 2005 Aug;206:83-99
pubmed: 16048543
Elife. 2016 Mar 04;5:
pubmed: 26943617
Cell. 2000 Sep 15;102(6):827-37
pubmed: 11030626
Curr Opin Investig Drugs. 2009 Nov;10(11):1212-24
pubmed: 19876789
J Vis Exp. 2011 Sep 02;(55):e3261
pubmed: 21912369
J Biol Chem. 2006 Mar 17;281(11):7075-81
pubmed: 16423833
J Cell Sci. 2017 Jan 15;130(2):307-314
pubmed: 28062847
Nat Rev Mol Cell Biol. 2002 Jul;3(7):531-7
pubmed: 12094219
Am J Respir Cell Mol Biol. 2005 Oct;33(4):363-70
pubmed: 15994431
Curr Biol. 2001 Jan 9;11(1):R35-8
pubmed: 11166195
MAbs. 2011 Jul-Aug;3(4):352-61
pubmed: 21691145
Viruses. 2018 May 03;10(5):
pubmed: 29751532
PLoS One. 2014 May 09;9(5):e96903
pubmed: 24816777
Curr Top Microbiol Immunol. 2006;308:173-204
pubmed: 16922091
J Clin Invest. 1995 Feb;95(2):493-502
pubmed: 7860731
Gene Ther. 2001 Apr;8(8):586-92
pubmed: 11320404
Mucosal Immunol. 2011 Nov;4(6):598-602
pubmed: 21956244
J Immunol. 2005 Nov 15;175(10):6694-701
pubmed: 16272325
Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):944-51
pubmed: 10712347
Annu Rev Biochem. 2013;82:775-97
pubmed: 23495938
Am J Respir Crit Care Med. 2003 May 15;167(10):1374-9
pubmed: 12615618
MAbs. 2019 Aug/Sep;11(6):1122-1138
pubmed: 31122132
J Exp Med. 2002 Aug 19;196(4):551-5
pubmed: 12186846
JCI Insight. 2018 Jun 21;3(12):
pubmed: 29925682
Mucosal Immunol. 2009 Jan;2(1):74-84
pubmed: 19079336
Mol Immunol. 2015 Nov;68(1):35-9
pubmed: 26597204
PLoS One. 2011;6(10):e26299
pubmed: 22022593
Immunol Rev. 1999 Oct;171:45-87
pubmed: 10582165
Appl In Vitro Toxicol. 2018 Jun 1;4(2):149-158
pubmed: 29904643

Auteurs

Bharathikumar Vellalore Maruthachalam (BV)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Adam Zwolak (A)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Xiefan Lin-Schmidt (X)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Edward Keough (E)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Ninkka Tamot (N)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Sathya Venkataramani (S)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Brian Geist (B)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Sanjaya Singh (S)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Rajkumar Ganesan (R)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH